Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($1.33), $0.48 better than the analyst estimate of ($1.81). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $3.42 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.